Santaris, Bristol-Myers partner to develop RNA-targeted medicines
Santaris’ proprietary Locked Nucleic Acid (LNA) drug platform will be used in the discovery and development of the novel medicines. The LNA Drug platform combines the company’s LNA
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.